https://doi.org/10.4081/monaldi.2023.2641
A comprehensive analysis of GATA3 expression in carcinomas of various origins with emphasis on lung carcinomas
Submitted: May 17, 2023
Accepted: July 27, 2023
Published: August 29, 2023
Accepted: July 27, 2023
Abstract Views: 453
PDF_early view: 289
Supplementary Table 1: 80
Supplementary Table 2: 77
Supplementary Table 1: 80
Supplementary Table 2: 77
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
GATA3 is a transcription factor involved in embryogenesis of multiple human tissues and in maintaining cell differentiation and tissue homeostasis in the adult organism. GATA3 is also involved in carcinogenesis and regarded as a sensitive marker for urothelial and breast carcinomas, albeit expression in carcinomas of non-breast/urothelial origin has been frequently reported. We sought to examine the extent and intensity of GATA3 expression in various carcinomas, mainly lung, urothelial, and breast and various other primary sites. Patients with breast carcinoma (N=40), carcinoma of the urinary bladder/renal pelvis (N=40), lung carcinoma (N=110) and various other origins (N=45) were included in the study. One hundred and sixty-five patients had a primary tumor diagnosis, and 70 cases had a metastatic tumor diagnosis. Our results showed that GATA3 expression was significantly more common in carcinomas of the breast, urinary bladder and renal pelvis compared to all other origins. All primary and 93% of metastatic urinary bladder carcinomas and 94% of the primary and 80% of metastatic breast carcinomas expressed GATA3. Expression was lower in non-urothelial histology of urinary primaries and in triple negative breast carcinomas. Focal staining, mostly faint, was seen in 5.6% of the primary lung adenocarcinomas and 35% of the primary lung squamous cell carcinomas. More extensive and intense staining was seen in 3.7% of the primary lung adenocarcinomas and 12% of the primary lung squamous cell carcinomas. Expression, mostly focal was also seen in 30% of the metastatic lung carcinomas. Finally, high expression was seen in 12.5% of the other tumors (one metastatic pancreatic carcinoma, one metastatic salivary gland adenocarcinoma NOS, one metastatic squamous cell carcinoma of the skin, one primary uterine cervix serous carcinoma, and one squamous cell carcinoma of the head and neck) and focal expression was present in another 22% of them. No ideal cut-off for positivity for GATA3 staining could be identified. In conclusion our study shows that GATA3 staining has two caveats in its use: the first is that non classical histologies of urothelial carcinomas and TNBC may be negative for the marker and secondly carcinomas of various origins may show (although rarely) intense positivity
Tremblay M, Sanchez-Ferras O, Bouchard M. GATA transcription factors in development and disease. Development 2018;145:dev164384.
DOI: https://doi.org/10.1242/dev.164384
Eeckhoute J, Keeton EK, Lupien M, et al. Positive cross-regulatory loop ties GATA-3 to estrogen receptor α expression in breast cancer. Cancer Res 2007;67:6477-83.
DOI: https://doi.org/10.1158/0008-5472.CAN-07-0746
Tanaka H, Takizawa Y, Takaku M, et al. Interaction of the pioneer transcription factor GATA3 with nucleosomes. Nat Commun 2020;11:4136.
DOI: https://doi.org/10.1038/s41467-020-17959-y
Huilgol D, Venkataramani P, Nandi S, Bhattacharjee S. Transcription factors that govern development and disease: An Achilles heel in cancer. Genes (Basel) 2019;10:794.
DOI: https://doi.org/10.3390/genes10100794
Zaidan N, Ottersbach K. The multi-faceted role of Gata3 in developmental haematopoiesis. Open Biol 2018;8:180152.
DOI: https://doi.org/10.1098/rsob.180152
Asselin-Labat ML, Sutherland KD, Barker H, et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 2007;9:201-9.
DOI: https://doi.org/10.1038/ncb1530
Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 2006;127:1041-55.
DOI: https://doi.org/10.1016/j.cell.2006.09.048
Grote D, Boualia SK, Souabni A, et al. Gata3 acts downstream of β-catenin signaling to prevent ectopic metanephric kidney induction. PLoS Genet 2008;4:e1000316.
DOI: https://doi.org/10.1371/journal.pgen.1000316
Chia I, Grote D, Marcotte M, et al. Nephric duct insertion is a crucial step in urinary tract maturation that is regulated by a Gata3-Raldh2-Ret molecular network in mice. Development 2011;138:2089-97.
DOI: https://doi.org/10.1242/dev.056838
Van Esch H, Groenen P, Nesbit MA, et al. GATA3 haplo-insufficiency causes human HDR syndrome. Nature 2000;406:419-22.
DOI: https://doi.org/10.1038/35019088
Rodrigues NP, Janzen V, Forkert R, et al. Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasis. Blood 2005;106:477-84.
DOI: https://doi.org/10.1182/blood-2004-08-2989
Qian L, Bodmer R. Partial loss of GATA factor Pannier impairs adult heart function in Drosophila. Hum Mol Genet 2009;18:3153-63.
DOI: https://doi.org/10.1093/hmg/ddp254
Tsarovina K, Reiff T, Stubbusch J, et al. The Gata3 transcription factor is required for the survival of embryonic and adult sympathetic neurons. J Neurosci 2010;30:10833-43.
DOI: https://doi.org/10.1523/JNEUROSCI.0175-10.2010
Frelin C, Herrington R, Janmohamed S, et al. GATA-3 regulates the self-renewal of long-term hematopoietic stem cells. Nat Immunol 2013;14:1037-44.
DOI: https://doi.org/10.1038/ni.2692
Usary J, Llaca V, Karaca G, et al. Mutation of GATA3 in human breast tumors. Oncogene 2004;23:7669-78.
DOI: https://doi.org/10.1038/sj.onc.1207966
Takaku M, Grimm SA, De Kumar B, et al. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3. Nucleic Acids Res 2020;48:4756-68.
DOI: https://doi.org/10.1093/nar/gkaa179
Emmanuel N, Lofgren KA, Peterson EA, et al. Mutant GATA3 actively promotes the growth of normal and malignant mammary cells. Anticancer Res 2018;38:4435-41.
DOI: https://doi.org/10.21873/anticanres.12745
Li Y, Ishiguro H, Kawahara T, et al. GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens. Am J Cancer Res 2014;4:461-73.
Li Y, Ishiguro H, Kawahara T, et al. Loss of GATA3 in bladder cancer promotes cell migration and invasion. Cancer Biol Ther 2014;15:428-35.
DOI: https://doi.org/10.4161/cbt.27631
Lin MC, Lin JJ, Hsu CL, et al. GATA3 interacts with and stabilizes HIF-1α to enhance cancer cell invasiveness. Oncogene 2017;36:4243-52.
DOI: https://doi.org/10.1038/onc.2017.8
Pezzuto A, Perrone G, Orlando N, et al. A close relationship between HIF-1α expression and bone metastases in advanced NSCLC, a retrospective analysis. Oncotarget 2019;10:7071-9.
DOI: https://doi.org/10.18632/oncotarget.27378
Zhu Z, Shen H, Xu J, et al. GATA3 mediates doxorubicin resistance by inhibiting CYB5R2-catalyzed iron reduction in breast cancer cells. Drug Resistance Updates 2023;69:100974.
DOI: https://doi.org/10.1016/j.drup.2023.100974
Chang A, Amin A, Gabrielson E, et al. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am J Surg Pathol 2012;36:1472-6.
DOI: https://doi.org/10.1097/PAS.0b013e318260cde7
Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol 2010;23:654-61.
Byrne DJ, Deb S, Takano EA, Fox SB. GATA3 expression in triple-negative breast cancers. Histopathology 2017;71:63-71.
DOI: https://doi.org/10.1111/his.13187
Querzoli P, Pedriali M, Rinaldi R, et al. GATA3 as an adjunct prognostic factor in breast cancer patients with less aggressive disease: a study with a review of the literature. Diagnostics 2021;11:604.
Grypari IM, Logotheti S, Zolota V, et al. The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progression. Medicine (Baltimore) 2021;100:e27094.
DOI: https://doi.org/10.1097/MD.0000000000027094
Davis DG, Siddiqui MT, Oprea-Ilies G, et al. GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas. Hum Pathol 2016;47:26-31.
DOI: https://doi.org/10.1016/j.humpath.2015.09.015
Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol 2010;23:654-61.
DOI: https://doi.org/10.1038/modpathol.2010.38
Mohammed KH, Siddiqui MT, Cohen C. GATA3 immunohistochemical expression in invasive urothelial carcinoma. Urol Oncol 2016;34:432.e9-432.e13.
DOI: https://doi.org/10.1016/j.urolonc.2016.04.016
Hoang LL, Tacha D, Bremer RE, et al. Uroplakin II (UPII), GATA3, and p40 are highly sensitive markers for the differential diagnosis of invasive urothelial carcinoma. Appl Immunohistochem Mol Morphol 2015;23:711-6.
DOI: https://doi.org/10.1097/PAI.0000000000000143
Leivo MZ, Elson PJ, Tacha DE, et al. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma. Pathology 2016;48:543-9.
DOI: https://doi.org/10.1016/j.pathol.2016.05.008
Dadhania V, Zhang M, Zhang L, et al. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine 2016;12:105-17.
DOI: https://doi.org/10.1016/j.ebiom.2016.08.036
Brandler TC, Aziz MS, Rosen LM, et al. Usefulness of GATA3 and p40 immunostains in the diagnosis of metastatic urothelial carcinoma in cytology specimens. Cancer Cytopathol 2014;122:468-73.
DOI: https://doi.org/10.1002/cncy.21424
Ellis CL, Chang AG, Cimino-Mathews A, et al. GATA-3 immunohistochemistry in the differential diagnosis of adenocarcinoma of the urinary bladder. Am J Surgl Pathol 2013;37:1756-60.
DOI: https://doi.org/10.1097/PAS.0b013e31829cdba7
Fatima N, Osunkoya AO. GATA3 expression in sarcomatoid urothelial carcinoma of the bladder. Hum Pathol 2014;45:1625-9.
DOI: https://doi.org/10.1016/j.humpath.2014.03.015
Liang Y, Heitzman J, Kamat AM, et al. Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol 2014;45:1466-72.
DOI: https://doi.org/10.1016/j.humpath.2014.02.023
Ni YB, Tsang JYS, Shao MM, et al. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer. Breast Cancer Res Treat 2018;169:25-32.
DOI: https://doi.org/10.1007/s10549-017-4645-2
Querzoli P, Pedriali M, Rinaldi R, et al GATA3 as an adjunct prognostic factor in breast cancer patients with less aggressive disease: A study with a review of the literature. Diagnostics 2021;11:604.
DOI: https://doi.org/10.3390/diagnostics11040604
Cakir A, Isik Gonul I, Ekinci O, et al GATA3 expression and its relationship with clinicopathological parameters in invasive breast carcinomas. Pathol Res Pract 2017;213:227-34.
DOI: https://doi.org/10.1016/j.prp.2016.12.010
Kawaguchi KR, Lu FI, Kaplan R, et al. In search of the ideal immunopanel to distinguish metastatic mammary carcinoma from primary lung carcinoma. Appl Immunohistochem Mol Morphol 2014;22:266-74.
DOI: https://doi.org/10.1097/PAI.0b013e318297cc0b
Kriegsmann K, Zgorzelski C, Muley T, et al. Immunohistological expression of oestrogen receptor, progesterone receptor, mammaglobin, human epidermal growth factor receptor 2 and GATA‐binding protein 3 in non‐small‐cell lung cancer. Histopathology 2020;77:900-14.
DOI: https://doi.org/10.1111/his.14203
Miettinen M, McCue PA, Sarlomo-Rikala M, et al. GATA3 - A multispecific but potentiall useful marker in surgical pathology-A systematic analysis of 2500 epithelial and non-epithelial tumors. Ame J Surg Pathol 2014;38:13-22.
DOI: https://doi.org/10.1097/PAS.0b013e3182a0218f
Gruver AM, Amin MB, Luthringer DJ, et al. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung. Arch Pathol Lab Med 2012;136:1339-46.
DOI: https://doi.org/10.5858/arpa.2011-0575-OA
Ethics Approval
The study protocol was approved by the University Hospital of Patras Committee for Research, Morality and EthicsHow to Cite
Bota, Eirini-Chrisovalanto, Dimitra Koumoundourou, Panagiota Ravazoula, Vasiliki Zolota, Charalampia Psachoulia, Maria Kardari, Theodoros Karampitsakos, Argyrios Tzouvelekis, Vasiliki Tzelepi, and Fotios Sampsonas. 2023. “A Comprehensive Analysis of GATA3 Expression in Carcinomas of Various Origins With Emphasis on Lung Carcinomas”. Monaldi Archives for Chest Disease, August. https://doi.org/10.4081/monaldi.2023.2641.
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
